Stem Cell Research is Slow but Jason Hope Says Its Future is Bright

Stem cell research and data had permeated the headlines. As a result, several independent companies, biotech giants, and startups have dove into stem cell-related projects. In addition, according to futurist Jason Hope, the interest will continue to grow.

Scientists harvested and cultured the first human embryonic stem cells in a lab over 20 years ago. Consequently, the medical sector experienced a new wave of advancements in the areas of Alzheimer’s, heart disease, Parkinson’s Disease, strokes, and anti-aging. That is why philanthropist Jason Hope is an avid activist investor for this type of research projects.

However, Hope concludes that despite the advances in stem cell research, bringing stem cell therapy to the public and developing at an acceptable level for scientists and the medical community still needs to happen. In other words, Jason Hope states, the right amount of research, testing, and development must still occur.

Otherwise, the public is likely to distrust a company that promotes stem cell therapy prematurely. To participate in the research still needed for stem cell treatment, Hope contributes to the SENS Organization (Strategies for Engineered Negligible Senescence). Jason Hope explains how the SENS works to stop a disease from happening rather than focusing on the treatment.

For example, stem cell treatments for Parkinson’s are currently in the second stage of clinical trials at SENS. In addition, research by other organizations is currently happening, such as ways to stop the liver from rejecting stem cells.

Jason Hope is aware of the potential risks, hurdles, and roadblocks associated with stem cell research. Therefore, he is aware that the stem cell research journey can be a bumpy one. He is also aware that this kind of research is inherently slow in developing. However, he asserts that overturning degenerative effects and improving the quality of life is worth the process.